NCT05910957Active, not recruitingNot Applicable
Multi-Omic, Clinomic and Digitomic Attributes of Major Depression for Integrative Analytics: the MACADAMIA Pilot Study
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Mayo Clinic
- Enrollment
- 40
- Locations
- 2
- Primary Endpoint
- Change in Quick Inventory of Depressive Symptoms-Clinician Rated (QIDS-CR) scale
Study Overview
Brief Summary
The purpose of this research is to see if information from blood and data from smartwatches can be combined to help diagnose depression and determine if transitions between active depression and treated depression can be predicted.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 20 Years to 62 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Participated in the BROWNIE study.
- •DSM-5 diagnostic criteria are met for unipolar, non-psychotic MDD (excluding controls).
- •A score of > 10 on the QIDS-C and QIDS-SR (equivalent to 13 or greater on HAM-D17) given that when medication exceeds the effect of placebo in primary care participants have a HAM-D17 >12 (excluding controls).
- •Antidepressant treatment is deemed appropriate by a study clinician (excluding controls).
- •Smart watch wear time is at least 70% during their participation in the BROWNIE study.
Exclusion Criteria
- •Subjects with medical contraindications that preclude treatment with study drugs will be excluded.
- •Patients with schizophrenia, schizoaffective disorder, or who have bipolar I or II disorder (or another specified or unspecified bipolar spectrum disorder) will be excluded because they have a primary psychiatric condition that requires a different initial treatment.
- •Subjects currently on antidepressant medication with subtherapeutic results in terms of depression management will undergo a medication taper and discontinuation prior to initiation of a new study medication. The subject will be closely monitored by the study clinician during the medication taper and discontinuation phase. The medication taper is left up to the study clinician's discretion. Study subjects who cannot be safely tapered from their medication or experience adverse effects during the taper will be excluded from the study.
- •Subjects who have an active substance use disorder will be excluded. An active substance use disorder will be defined as meeting DSM-5 diagnostic criteria for any active substance use disorder. Persons meeting DSM-5 diagnostic criteria for a substance use disorder in full remission (>12 months) and a negative urine drug of abuse screen at the screening visit or before the baseline study visit will be considered eligible. Persons with a positive urine drug of abuse screen may participate in the study if they do not meet DSM-5 diagnostic criteria for a substance use disorder.
- •Subjects unable to give informed consent or who are unwilling or unable to comply with study requirements are excluded.
- •Pregnant subjects will be excluded.
- •Subjects who are currently breastfeeding and who plan to continue breastfeeding will be excluded.
- •Subjects who are psychiatrically hospitalized or in a mental health crisis requiring urgent care or psychiatric hospitalization.
- •Study subjects currently on antipsychotic medications (e.g., typical, and atypical antipsychotic drugs) taken for primary psychotic illness or affective psychosis will be excluded.
- •Study subjects taking mood stabilizing agents (e.g., lithium, carbamazepine, valproate, lamotrigine, gabapentin, or other anticonvulsants) taken specifically for bipolar spectrum disorders are not eligible for participation.
Outcomes
Primary Outcomes
Change in Quick Inventory of Depressive Symptoms-Clinician Rated (QIDS-CR) scale
Time Frame: Baseline, 4 weeks, and 8 weeks
The Quick Inventory of Depressive Symptoms-Clinician Rated is used for rating the severity of depressive symptoms. Possible scores range from 0 to 27, with higher scores indicating greater severity of depression.
Secondary Outcomes
- Change in Hamilton Depression Rating Scale(Baseline, 4 weeks, and 8 weeks)
Investigators
Mohit Chauhan, M.B.B.S.
Principal Investigator
Mayo Clinic
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Assesment of Multiomics Profiles in Health and Disease.Genetic Predisposition to DiseaseNCT04427163The Institute of Molecular and Translational Medicine, Czech Republic1,100
Completed
Not Applicable
Novel Objective Digital Biomarkers for Assessing Sub-clinical Mood Disturbances in the Singaporean PopulationMoodNCT06115590Institute for Human Development and Potential (IHDP), Singapore120
Completed
Not Applicable
Molecular and Clinical Response to a Single Bout of Aerobic Exercise in a Multimorbid Population: a Study From the Consortium on Precision EXercise in AgingMultimorbidity - End-stage Kidney DiseaseNCT05404698Université de Sherbrooke10
Not yet recruiting
Not Applicable
Perspectives of multi-OMICS analysis from blood, saliva and tumor tissue in patients with oral cavity carcinomas with regard to diagnostics, therapy and recurrence detection.DRKS00030492Bundeswehrkrankenhaus Ulm400
Completed
Not Applicable
Respiratory Infection MonitoringChronic Obstructive Pulmonary Disease (COPD)NCT04362631Northwestern University42